Arlington Capital Partners' portfolio company, AVS Bio, has expanded its capabilities in antibody discovery and protein production through the acquisition of ImmunoPrecise Antibodies Europe from ImmunoPrecise Antibodies Ltd. This strategic move enhances AVS Bio's European presence, adding advanced services in antibody discovery, protein expression, and organoid growth factor development to its portfolio. With facilities in Utrecht and Oss, Netherlands, ImmunoPrecise Antibodies Europe provides comprehensive services to biotechnology and pharmaceutical companies, supporting the development of next-generation biologics. Post-acquisition, the company will continue to operate under its current management as a key European hub within the AVS Bio network, serving global pharmaceutical markets.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。